Navigation Links
Raised Breast Cancer Risk Persists After Combo HRT Stopped
Date:3/4/2008

Latest data from Women's Health Initiative points to continued need for mammograms

TUESDAY, March 4 (HealthDay News) -- An increased risk of breast cancer lingers after a woman stops taking combination hormone replacement therapy, a new study shows.

The finding, published in the March 5 issue of the Journal of the American Medical Association, was based on data from the landmark Women's Health Initiative (WHI). That trial was halted abruptly in 2002, when it was discovered that postmenopausal women taking combination hormone therapy (estrogen plus progestin) had a higher risk of cardiovascular disease, stroke, blood clots and breast cancer.

"Within a couple of years, the [raised] risk for stroke, serious blood clots and heart attack disappears, but so do the benefits to bone," added study author Marcia Stefanick, a professor of medicine at Stanford University. "The concerning issue is the risk for all cancers remains significantly elevated, mostly because of breast cancer."

Stefanick said it wasn't clear if these were new breast cancers or existing tumors that had not been detected while women were still taking hormone therapy. A study in the Archives of Internal Medicine last week found women taking combined hormone therapy for about five years had a higher risk of abnormal mammograms and breast biopsies. This, in turn, may decrease the effectiveness of these methods for detecting breast cancer.

Dr. James Liu, chairman of obstetrics and gynecology at MacDonald Women's Hospital at Case Medical Center, University Hospitals, in Cleveland, emphasized that the results applied only to women taking combination hormone therapy, and that there may indeed be a delay involved. "The good news is that these changes do reverse," he said. "There may be some lag time in the breast risk, but because the breast risk actually increases with age independent of estrogen, women still should continue to have annual surveillance."

Stefanick is chairwoman of the WHI investigator group, and Liu was the principal investigator for the WHI in Cincinnati until 2001.

The current research followed 15,730 of the original WHI participants for an average of three years after the trial ended.

The risk of cardiovascular problems was similar in the HRT and placebo groups (1.97 percent and 1.91 percent, respectively). However, there was a greater risk of overall cancer in the HRT group (1.56 percent of participants) as compared with the placebo group (1.26 percent). Most of this was explained by a heightened risk of breast cancer, the researchers said.

Lung cancer risk was slightly higher but not enough to draw any firm conclusions. "It's not such a big study that you can see all the things you need to see when you look across the population," Stefanick said. "The people who are actually studying cancer across the whole population will start to potentially identify other cancers that are related to the combination therapy."

Death from any cause was 15 percent higher in the HRT group than in the placebo group.

Putting all these factors together, the risks of combined HRT exceed the benefits, the authors stated.

"The really important message for women is they need to get a mammogram if they've stopped using hormones," Stefanick said. "They shouldn't think everything is fine. They need to get a mammogram to make absolutely sure. Once they've stopped the hormones, you have a better chance of detecting them."

Follow-up data in the estrogen-alone arm of the WHI is not yet available.

More information

The National Heart, Lung, and Blood Institute has more on the Women's Health Initiative.



SOURCES: Marcia Stefanick, Ph.D., professor, medicine, Stanford University; James Liu, M.D., chairman, department of obstetrics and gynecology, MacDonald Women's Hospital, Case Medical Center, University Hospitals, Cleveland; March 5, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kidney Awareness Time (KAT) Walk Raised Awareness and $400,000 for Kidney Education and Prevention Programs
2. Babies raised in bilingual homes learn new words differently than infants learning one language
3. High Levels of Stress After 9/11 Raised Heart Disease Risk
4. Survival differences by race most apparent in advanced stages of breast cancer
5. MRI finds breast cancer before it becomes dangerous
6. Pathway links inflammation, angiogenesis and breast cancer
7. Drop in breast cancer incidence linked to hormone use, not mammograms
8. Breast cancer prevention practices vary across Canada
9. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
10. Acrylamide Wont Raise Breast Cancer Risk
11. New link between estrogen and breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Raised Breast Cancer Risk Persists After Combo HRT Stopped
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers ... alternative to dairy proteins, providing direct cost savings as well as more stable ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: